Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2017-11-13
Target enrollment:
Participant gender:
Summary
This clinical trial studies potential genetic markers which might be used to predict which
patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine. This
study will contribute to the efforts to find effective and less toxic therapies to provide
durable remissions in a significant proportion of elderly AML patients.